Bollard Group’s Revolution Medicines RVMD Stock Holding History

Bollard Group’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-86,800	Closed	-$2.21M	–	389
2022 Q1	$2.21M	Buy	+86,800	New	+$1.89M	0.07%	105

Other funds holding RVMD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bollard Group's RVMD Position: Q2 2022 in Review

Bollard Group sold out of Revolution Medicines (RVMD) in Q2 2022, closing a stake of 86,800 shares — an estimated $2.21M sold.

Bollard Group first reported a position in RVMD in Q1 2022 and held it in 1 quarter. The position peaked at $2.21M in Q1 2022. 135 funds tracked by Wall St. Rank hold RVMD as of Q2 2022.

Bollard Group reported no remaining Revolution Medicines position as of Q2 2022 after selling out during the quarter.
Bollard Group sold 86,800 Revolution Medicines shares in Q2 2022, an estimated $2.21M.
Bollard Group first reported a position in Revolution Medicines in Q1 2022 and held it in 1 quarter.
Bollard Group's Revolution Medicines position peaked at $2.21M in Q1 2022.
135 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.